James Ermer - Concepedia

Author

James Ermer

Takeda (United States)

Also Known As

J C Ermer, J ERMER, J Ermer, J. Ermer, James C Ermer, James C. Ermer, James Ermer

Publications

777

Citations

H-Index

Concepts

All Affiliations

Takeda (United States)Shine Micro (United States)Clinical Pharmacology of Miami Hackensack University Medical Center University at Buffalo, State University of New York

About

James Ermer is an author at Takeda (United States) specializing in pharmacology, medicine, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	328
2	Endocrinology	4	4	82
3	Social Sciences	2	2	29
4	Anesthesia	1	1	73
5	Gastroenterology	1	1	35

James Ermer

Publications

553

Citations

H-Index

Page 1

	Year	Citations
Effects of route of administration and repetitive dosing on the disposition kinetics of di(2-ethylhexyl) phthalate and its mono-de-esterified metabolite in rats Gary M. Pollack, Ron C.K. Li, James Ermer, Toxicology and Applied Pharmacology Mono-de-esterified MetabolitePharmacological StudyMedicineRepetitive DosingToxicology	1985	87
Lisdexamfetamine Dimesylate: Linear Dose‐Proportionality, Low Intersubject and Intrasubject Variability, and Safety in an Open‐Label Single‐Dose Pharmacokinetic Study in Healthy Adult Volunteers James Ermer, Robert Homolka, Patrick Martin, The Journal of Clinical Pharmacology PharmacotherapyBlood PressureLisdexamfetamine DimesylatePharmacodynamic ModelingHealthy Adult Volunteers	2010	73
Pharmacokinetics of promethazine hydrochloride after administration of rectal suppositories and oral syrup to healthy subjects Laura C. Strenkoski‐Nix, James Ermer, Sheryl DeCleene, American Journal of Health-System Pharmacy Dosage StrengthsHealthy SubjectsPharmacological StudyGastrointestinal PharmacologyMedicine	2000	35
Intranasal versus Oral Administration of Lisdexamfetamine Dimesylate James Ermer, Kerry Dennis, Mary B. Haffey, Clinical Drug Investigation Lisdexamfetamine DimesylateMedicinePharmacotherapyPharmacologyAnesthetic Pharmacology	2011	35
Effects of Omeprazole on the Pharmacokinetic Profiles of Lisdexamfetamine Dimesylate and Extended-Release Mixed Amphetamine Salts in Adults Mary B. Haffey, Mary Buckwalter, Pinggao Zhang, Postgraduate Medicine	2009	34
Accumulation and Washout Kinetics of Valproic Acid and Its Active Metabolites Gary M. Pollack, William B. McHugh, Francis Gengo, The Journal of Clinical Pharmacology	1986	31
Bazedoxifene Acetate Dose Proportionality in Healthy, Postmenopausal Women James Ermer, William McKeand, Patti Sullivan, Clinical Pharmacology & Therapeutics GynecologyPharmacotherapyPharmacodynamic ModelingPre-clinical PharmacologyMolecular Pharmacology	2003	29
Absolute/Relative Bioavailability of Bazedoxifene Acetate in Healthy Postmenopausal Women Alain Patat, William McKeand, Susan Baird‐Bellaire, Clinical Pharmacology & Therapeutics Molecular PharmacologyTranslational PharmacologyPharmacological StudyClinical TherapeuticMedicine	2003	23
Pharmacokinetics of Lisdexamfetamine Dimesylate after Targeted Gastrointestinal Release or Oral Administration in Healthy Adults James Ermer, Mary B. Haffey, W Döll, Drug Metabolism and Disposition	2011	21
Bioavailability of triple-bead mixed amphetamine salts compared with a dose-augmentation strategy of mixed amphetamine salts extended release plus mixed amphetamine salts immediate release James Ermer, Amir Shojaei, Michael Pennick, Current Medical Research and Opinion	2007	20

Page 1